Balchem Co. (NASDAQ:BCPC – Get Rating) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 375,600 shares, a decline of 23.5% from the March 15th total of 490,900 shares. Based on an average daily volume of 131,300 shares, the short-interest ratio is presently 2.9 days. Currently, 1.2% of the company’s stock are short sold.
A number of hedge funds and other institutional investors have recently made changes to their positions in BCPC. Annex Advisory Services LLC raised its stake in Balchem by 61.3% in the 1st quarter. Annex Advisory Services LLC now owns 13,737 shares of the basic materials company’s stock valued at $1,878,000 after acquiring an additional 5,219 shares during the period. Maryland State Retirement & Pension System raised its position in shares of Balchem by 0.6% in the first quarter. Maryland State Retirement & Pension System now owns 12,985 shares of the basic materials company’s stock valued at $1,775,000 after purchasing an additional 75 shares during the period. Nordea Investment Management AB lifted its stake in shares of Balchem by 26.3% during the 1st quarter. Nordea Investment Management AB now owns 81,511 shares of the basic materials company’s stock worth $11,186,000 after buying an additional 16,982 shares during the last quarter. Norges Bank bought a new stake in shares of Balchem during the 4th quarter worth about $50,016,000. Finally, Bill Few Associates Inc. acquired a new position in Balchem in the 4th quarter valued at about $240,000. 89.10% of the stock is currently owned by hedge funds and other institutional investors.
Shares of BCPC opened at $133.42 on Monday. The company has a current ratio of 2.24, a quick ratio of 1.61 and a debt-to-equity ratio of 0.14. The company’s fifty day simple moving average is $137.32 and its 200 day simple moving average is $150.78. Balchem has a 1-year low of $119.59 and a 1-year high of $174.29. The company has a market cap of $4.29 billion, a price-to-earnings ratio of 45.23 and a beta of 0.62.
Several equities research analysts have commented on the company. HC Wainwright cut their target price on Balchem from $170.00 to $155.00 and set a “buy” rating on the stock in a research note on Tuesday, March 8th. StockNews.com began coverage on shares of Balchem in a research report on Thursday, March 31st. They issued a “buy” rating on the stock. Zacks Investment Research downgraded shares of Balchem from a “hold” rating to a “sell” rating in a research report on Monday, March 14th. Finally, Sidoti raised shares of Balchem from a “neutral” rating to a “buy” rating and set a $175.00 price target on the stock in a research report on Tuesday, February 22nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Balchem currently has a consensus rating of “Hold” and a consensus price target of $160.50.
Balchem Company Profile (Get Rating)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets in the United States and internationally. It operates through three segments: Human Nutrition & Health, Animal Nutrition & Health, and Specialty Products.
- Get a free copy of the StockNews.com research report on Balchem (BCPC)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
Receive News & Ratings for Balchem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Balchem and related companies with MarketBeat.com's FREE daily email newsletter.